| 王 影,刘 云,王海丽,岳 婷,许林波.1g/h与2g/h硫酸镁维持剂量输注期间的血清镁水平预防子痫效果[J].现代生物医学进展英文版,2021,(21):4171-4175. |
| 1g/h与2g/h硫酸镁维持剂量输注期间的血清镁水平预防子痫效果 |
| Effect of Serum Magnesium Level on Prevention of Eclampsia During Maintenance Dose Infusion of 1 g/h and 2 g/h Magnesium Sulfate |
| Received:April 02, 2021 Revised:April 25, 2021 |
| DOI：10.13241/j.cnki.pmb.2021.21.036 |
| 中文关键词: 硫酸镁 维持剂量 子痫 |
| 英文关键词: Magnesium sulfate Maintenance dose Eclampsia |
| 基金项目:陕西省重点研发计划项目（2020SF-037）；陕西省人民医院科技发展基金项目（2020YXM-11） |
|
| Hits: 699 |
| Download times: 393 |
| 中文摘要: |
| 摘要 目的：探究硫酸镁不同维持剂量在预防子痫中的临床效果分析。方法：选择2018年1月至2020年1月于我院接受治疗的100例子痫前期产妇，按照随机数字表法区分为研究组与对照组（每组各50例产妇），对照组产妇接受1 g/h硫酸镁维持剂量输注，研究组产妇接受2 g/h硫酸镁维持剂量输注，对比两组产妇干预前后血压、24 h尿蛋白、血浆纤维蛋白原、尿钙黏蛋白变化，统计两组产妇临床疗效差异以及不良反应发生情况。结果：（1）研究组治疗总有效率为98.00 %，高于对照组的86.00 %（P<0.05）；（2）干预前两组产妇收缩压和舒张压组间无差异（P>0.05），治疗后研究组收缩压和舒张压均低于对照组（P<0.05）；（3）干预前两组产妇24 h尿蛋白、血浆纤维蛋白原水平组间无差异（P>0.05），治疗后研究组上述指标均低于对照组（P<0.05），但两组干预前后血清镁水平无差异（P>0.05）；（4）研究组不良反应总发生率14.00 %，显著高于对照组的2.00 %（P<0.05）。结论：对子痫产妇持续输注2 g/h硫酸镁可以有效改善其临床症状，降低产妇血压水平，控制其疾病进展效果较好，但不良反应发生情况显著高于持续输注1 g/h硫酸镁的产妇。 |
| 英文摘要: |
| ABSTRACT Objective: To explore the clinical effect of different maintenance doses of magnesium sulfate in the prevention of eclampsia. Methods: A total of 100 lying-in women with preeclampsia,who were treated in Shaanxi Provincial People's Hospital from January 2018 to January 2020, were selected and were randomly divided into research group(n=50) and control group(n=50). The control group received 1 g/h magnesium sulfate maintenance dose infusion, and the research group received 2 g /h magnesium sulfate maintenance dose infusion. The clinical curative effects and adverse reactions of two groups of lying-in women were compared and analyzed. Results: (1) The total effective rate(98.00 %) of the study group was higher than that(86.00 %) of the control group (P<0.05). (2) Before the intervention, there was no significant difference between the two groups(P>0.05). The systolic and diastolic blood pressure in the study group were lower than those in the control group after treatment(P<0.05). (3) There was no significant difference in 24-hour urinary protein and plasma fibrinogen levels between the two groups before intervention(P>0.05). The above indexes in the study group were lower than those in the control group after treatment (P<0.05), but there was no significant difference in serum magnesium levels between the two groups before and after intervention (P>0.05). (4) The total incidence of adverse reactions(14.00 %) in the study group was significantly higher than that(2.00 %) in the control group(P<0.05). Conclusion: Continuous infusion of 2 g/h magnesium sulfate can effectively improve the clinical symptoms, reduce maternal blood pressure, and control the disease progression, but the incidence of adverse reactions is significantly higher than that of continuous infusion of 1 g/h magnesium sulfate. |
|
View Full Text
View/Add Comment Download reader |
| Close |
